Outcomes after Matched Unrelated Donor and Haploidentical Related Donor Allogeneic Transplantation for Hematological Malignancies: Single Center Experience

Slides:

Advertisements

Similar presentations

Comparison of Outcomes with Two Calcineurin Inhibitor-Based Graft-Versus-Host- Disease Prophylactic Regimens after Reduced Intensity Conditioning Allogeneic.

Advertisements

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review

Efficacy and Safety of Ciprofloxacin for Prophylaxis of Polyomavirus BK Virus– Associated Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplantation.

How to Treat MDS without Stem Cell Transplantation

Assessment of Safety and Efficacy of Peripheral Blood Stem Cell (PBSC) Mobilization with G-CSF in Haploidentical Maternal Donors with Sickle Cell Trait.

T-Cell Acute Lymphoblastic Lymphoma (T-LBL) and Stem Cell Transplantation (SCT): A Comparison of Outcomes with T-Cell Acute Lymphoblastic Leukemia (T-ALL)

Improvement in Hematopoiesis with Treatment of Iron Overload Following Allogeneic Transplants Akash Mukherjee, MD, Dhaval Shah, MD, Gloria Obi, PhD,

Influence of Stem Cell Source on Outcomes of Allogeneic Reduced-Intensity Conditioning Therapy Transplants Using Haploidentical Related Donors Kenneth.

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

Familial Haploidentical (FHI) Allogeneic Stem Cell Transplantation Utilizing CD34 Enrichment and T Cell Addback in Children, Adolescents & Adults with.

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Allogeneic Hematopoietic Cell Transplantation (HCT) Results in Better Time to Next Therapy (TTNT) Than Chemotherapy (CT) in Chronic Lymphocytic Leukemia.

Proteomic Biomarkers Are Predictive of Non-Relapse Mortality in Patients Treated with Post-Transplantation Cyclophosphamide Following HLA-Haploidentical.

Acute Graft-Versus-Host Disease in the Setting of T Cell Depletion: Validation of a New Agvhd Risk Score Hayder Saeed, MD, Stacey Slone, MS, Swati Yalamanchi,

Biology of Blood and Marrow Transplantation

Higher Apheresis Blood Volumes Are Associated with a Reduction in Relapse Risk and Improved Survival in Patients Undergoing Reduced Intensity Allogeneic.

Low Incidence of Chronic GVHD after HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post Transplantation Cyclophosphamide in Older.

Access to Hematopoietic Cell Transplantation in the United States

Comparison of Outcomes with Two Calcineurin Inhibitor-Based Graft-Versus-Host- Disease Prophylactic Regimens after Reduced Intensity Conditioning Allogeneic.

CD34-Selected, T Cell Depleted Haploidentical Donor Peripheral Blood Stem Cell (PBSC) Transplantation in Children with Malignant (MD) and Non-Malignant.

Outcome of Transplantation for Myelofibrosis

Carol Ann Huff, Ephraim J. Fuchs, B

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Betty T. Tran, Abigail Halperin, Jason W. Chien

David C. Yao, MD, PhD, Paolo Caimi, MD, Hillard M

Jane Kempenich, Kelly Buck, John Hermanson, Jason Dehn, MPH

Brentuximab Vedotin Is Associated with Improved Progression-Free Survival after Allogeneic Transplantation for Hodgkin Lymphoma Robert Chen, Joycelynne.

High Rate of Long Term Complete Remission for Patients with Chronic Lymphocytic Leukemia (CLL) Who Relapse after Allogeneic Stem Cell Transplantation.

Pauline A. Daniels, DO, Stella M

Low Relapse without Excessive Transplant-Related Mortality following Myeloablative Cord Blood Transplantation for Acute Leukemia in Complete Remission:

Early Use of Inhaled Ribavirin Can Improve Outcomes in High Risk Hematopoietic Stem Cell Transplant and Leukemia Patients with RSV Infection Ron Mihelic,

Biology of Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation

A Novel Strategy in Managing Post-Liver Transplant Acute Graft-Versus-Host-Disease: The New Era (T)Rojan Horse Zeyad Kanaan, MD, William Tse, MD, FACP

Efficacy of Desensitization Therapy for Donor-Specific Anti-HLA Antibodies in Patients Undergoing Haploidentical Hematopoietic Cell Transplant Jordan.

Consistent Collection and Processing of Non-Mobilized Mononuclear Cell, Apheresis Products from HLA Haploidentical Bone Marrow Donors for Sequential CD3+

Long-Term Outcomes of Critically Ill Adult Allogeneic Hematopoietic Stem Cell Recipients Prakash Vishnu, Udit Roy, Pramod Guru, Colleen Thomas, Candido.

Treatment of High-Risk Sickle Cell Disease (SCD) with Familial Haploidentical (FHI) T- Cell Depleted (TCD) Stem Cell Transplantation with T-Cell Addback.

David A. Rizzieri, MD, Arati V

GVHD Prophylaxis with Post-Transplant High Dose Cyclophosphamide: Impact on Engraftment, Treatment-Related Mortality and Resource Utilization Nasheed.

Impact of Obesity on Clinical Outcomes of Elderly Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies Ensi Voshtina,

Identification of Potential Barriers and Incentives for BMT Nurses to Apply for and Maintain BMTCN Certification Brittney Nicole Browne, BSN, RN, OCN,

Infection Prevention - Visitors and the Best of Intentions

Integrative Therapy Use as a Comfort Measure with BMT Patients

The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation? Melhem.

Haploidentical Bmt and Post Transplant Cyclophosphamide: First Peruvian Experience Alfredo Wong, Mariela Moreno, Mayra Castillo, Juan Navarro, Lourdes.

A Successful Approach to Decreasing Central Line Associated Blood Stream Infections Colleen Butcher, RN, BSN, OCN, Cindy Kramer, RN, BSN, OCN, Carrie.

Robust Donor Chimerism and Engraftment Following Familial Haploidentical (FHI) (CD34 Enriched and T-Cell Addback) Allogeneic Stem Cell Transplantation.

The Role for Induction Chemotherapy and Allogeneic Stem Cell Transplant in Patients with Chronic Myelomonocytic Leukemia That Have Undergone Leukemic.

Outcomes of Second Unrelated Donor Cord Blood Transplants (UCBT) Performed in Children with Graft Failure of Autologous Recovery Following the First UCBT

Toxicities and Outcomes for Patients with CNS Lymphoma (CNSL) Consolidated with High-Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT)

September Mitchell, BSN, MHI, RN, CHTC, OCN, Sarah L

T Cell–Replete HLA Haploidentical Donor Transplantation with Post-Transplant Cyclophosphamide Is an Effective Salvage for Patients Relapsing after an.

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Elderly Patients with Acute Lymphoblastic Leukemia/Lymphoma: The Mayo Clinic Experience

Biology of Blood and Marrow Transplantation

Management of Cytokine Release Syndrome (CRS) in Patients Undergoing Chimeric Antigen Receptor Modified (CAR) T-Cell Therapy Following Autologous Stem.

Biology of Blood and Marrow Transplantation

Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients.

Prediction of Bloodstream Infection Due to Vancomycin-Resistant Enterococcus in Patients with Hematological Malignancy Undergoing Induction Therapy or.

Biology of Blood and Marrow Transplantation

Leading the Frontier: Successful Integration of an Adult BMT Hospital-Based Outpatient Practice Brenda Frye, PA-C, DHSc, Patricia McLean, APRN, CNP,

Treatment versus Transplant for Challenging Hematologic Disorders

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

Long-Term Outcomes of Patients with Advanced Mantle Cell Lymphoma Treated with Allogeneic Hematopoietic Cell Transplantation after Nonmyeloablative Conditioning

Pre-Transplant Comorbidity As an Outcome Predictor in Hematopoietic Cell Transplantation for Severe Aplastic Anemia SungNam Lim, Je-Hwan Lee, MD, PhD,

Monocyte Recovery at Day 100 Is Associated with Improved Survival in Multiple Myeloma Patients Who Undergo Allogeneic Hematopoietic Cell Transplantation

Comparison of Two Doses of Antithymocyte Globulin in Patients Undergoing Matched Unrelated Donor Allogeneic Stem Cell Transplantation Francis Ayuk, Galina.

Mismatched Related and Unrelated Donors for Allogeneic Hematopoietic Cell Transplantation for Adults with Hematologic Malignancies Mary Eapen, Paul O'Donnell,

In Memoriam: E. Donnall Thomas

The Incidence and Outcomes of Oral Mucositis Among Allogeneic Stem Cell Transplantation Patients: A Systematic Review and Meta-Analysis Hafsa Myedah.

Presentation transcript:

Outcomes after Matched Unrelated Donor and Haploidentical Related Donor Allogeneic Transplantation for Hematological Malignancies: Single Center Experience Ridhi Gupta, MD, Rashmi Khanal, MD, Mark Thomas Burbridge, DO, Elizabeth garrett Mayer, Ellen Baldino, PA-C, MEd, Colleen Butcher, BSN, RN, OCN, Kylie Capdevil, Kathy Hogan Edwards, PharmD, Carolyn Ann Gentles, MSN, FNP, Randi Hoffman, PhD, RN, C-NP, Amanda Littleton, RN, BSN, OCN, Kristy Martin, SRA, Cindy Kramer, RN, BSN, OCN, Molly Schneider, BSN, RN, APHON, Valeriy Sedov, MD, Juan Carlos Varela, MD, PhD, Elizabeth J. Williams, CQIA, Robert Stuart, MD, Saurabh Chhabra, MD Biology of Blood and Marrow Transplantation Volume 22, Issue 3, Pages S370-S371 (March 2016) DOI: 10.1016/j.bbmt.2015.11.880 Copyright © 2016 Terms and Conditions

Figure 1 Kaplan Meier curves comparing OS for URD and HRD. Biology of Blood and Marrow Transplantation 2016 22, S370-S371DOI: (10.1016/j.bbmt.2015.11.880) Copyright © 2016 Terms and Conditions

Figure 2 Competing Risks Analysis of Non-Relapse Mortality (NRM) and Relapse Associated Mortality. Biology of Blood and Marrow Transplantation 2016 22, S370-S371DOI: (10.1016/j.bbmt.2015.11.880) Copyright © 2016 Terms and Conditions